Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03870750 · ClinicalTrials.gov registry record · Phase 2
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 458
- Enrollment target
NCT03870750 is a Phase 2 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 458 participants.
The verdict
NCT03870750, a Phase 2 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 458 participants
- Enrollment target
Study Summary
This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects. While a second approach, clinical management of comorbidities (CMC) focuses on managing multiple diseases, other than cancer, such as heart or lung diseases through physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education. Giving SPC, CMC, or a combination of both may work better in improving quality of life and survival after a donor stem cell transplant compared to standard of care in patients with blood diseases.
Interventions
- OTHER Questionnaire Administration
- OTHER Best Practice
- PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
- OTHER Clinical Management
- OTHER Supportive Palliative Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03870750
The ClinicalTrials.gov registry entry for NCT03870750 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Questionnaire Administration is the first listed.
NCT03870750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03870750 about?
NCT03870750 is a clinical study titled "Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases". This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and...
What is the current status of trial NCT03870750?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 458 participants. The study started on 2019-08-15. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT03870750?
The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE), Clinical Management (OTHER), Supportive Palliative Care (OTHER).
Who is sponsoring clinical trial NCT03870750?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.